CA2378846A1 - Vaccin - Google Patents

Vaccin Download PDF

Info

Publication number
CA2378846A1
CA2378846A1 CA002378846A CA2378846A CA2378846A1 CA 2378846 A1 CA2378846 A1 CA 2378846A1 CA 002378846 A CA002378846 A CA 002378846A CA 2378846 A CA2378846 A CA 2378846A CA 2378846 A1 CA2378846 A1 CA 2378846A1
Authority
CA
Canada
Prior art keywords
protein
leu
ser
gly
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002378846A
Other languages
English (en)
Inventor
Silva Teresa Cabezon
Clifford Dillon Davin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
SmithKline Beecham Biologicals SA
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/352,616 external-priority patent/US6395278B1/en
Priority claimed from US09/439,313 external-priority patent/US6329505B1/en
Priority claimed from US09/570,737 external-priority patent/US7202342B1/en
Priority claimed from US09/593,793 external-priority patent/US7517952B1/en
Priority claimed from GB0015747A external-priority patent/GB0015747D0/en
Application filed by SmithKline Beecham Biologicals SA, Corixa Corp filed Critical SmithKline Beecham Biologicals SA
Publication of CA2378846A1 publication Critical patent/CA2378846A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne de nouvelles protéines et leur production, à partir de la famille de prostases. En particulier, l'invention a pour objet une protéine de prostase ou un fragment de cette dernière, liée à un partenaire de fusion immunologique, comme le NS1. Ces antigènes peuvent être formulés pour obtenir des vaccins pour traiter des tumeurs de la prostate. L'invention a aussi pour objet de nouveaux procédés permettant de purifier la protéine de prostase et les homologues.
CA002378846A 1999-07-13 2000-07-11 Vaccin Abandoned CA2378846A1 (fr)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US09/352,616 1999-07-13
US09/352,616 US6395278B1 (en) 1997-02-25 1999-07-13 Prostate specific fusion protein compositions
US09/439,313 US6329505B1 (en) 1997-02-25 1999-11-12 Compositions and methods for therapy and diagnosis of prostate cancer
US09/439,313 1999-11-12
US44368699A 1999-11-18 1999-11-18
US09/443,686 1999-11-18
US48367200A 2000-01-14 2000-01-14
US09/483,672 2000-01-14
US53685700A 2000-03-27 2000-03-27
US09/536,857 2000-03-27
US56810000A 2000-05-09 2000-05-09
US09/568,100 2000-05-09
US09/570,737 US7202342B1 (en) 1999-11-12 2000-05-12 Compositions and methods for the therapy and diagnosis of prostate cancer
US09/570,737 2000-05-12
US09/593,793 US7517952B1 (en) 1997-02-25 2000-06-13 Compositions and methods for the therapy and diagnosis of prostate cancer
US09/593,793 2000-06-13
US60578300A 2000-06-27 2000-06-27
US09/605,783 2000-06-27
GB0015747.9 2000-06-27
GB0015747A GB0015747D0 (en) 2000-06-27 2000-06-27 Vaccine
PCT/EP2000/006618 WO2001004143A2 (fr) 1999-07-13 2000-07-11 Vaccin

Publications (1)

Publication Number Publication Date
CA2378846A1 true CA2378846A1 (fr) 2001-01-18

Family

ID=27579342

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002378846A Abandoned CA2378846A1 (fr) 1999-07-13 2000-07-11 Vaccin

Country Status (5)

Country Link
EP (1) EP1194571A1 (fr)
JP (1) JP2003504080A (fr)
AU (1) AU6158700A (fr)
CA (1) CA2378846A1 (fr)
WO (1) WO2001004143A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083796B2 (en) * 2000-06-20 2006-08-01 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
US7022497B1 (en) 1999-03-11 2006-04-04 Mt. Sinai Hospital Human kallikrein-like genes
AU7753700A (en) * 1999-10-07 2001-05-10 Schering Aktiengesellschaft Dna encoding prost 07 polypeptide
GB0015722D0 (en) * 2000-06-27 2000-08-16 Smithkline Beecham Sa Vaccine
GB0015736D0 (en) * 2000-06-27 2000-08-16 Smithkline Beecham Biolog Vaccine
WO2009046739A1 (fr) 2007-10-09 2009-04-16 Curevac Gmbh Composition pour traiter le cancer de la prostate (pca)
WO2010037408A1 (fr) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprenant un arnm complexé et un arnm nu pour déclencher ou augmenter une réponse immunostimulante chez un mammifère et utilisations de ladite composition
WO2011009173A1 (fr) * 2009-07-23 2011-01-27 Mater Medical Research Institute Immunothérapie des cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3686178T2 (de) * 1985-02-07 1993-03-11 Smithkline Beckman Corp Malaria-impfstoff.
US5786148A (en) * 1996-11-05 1998-07-28 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a novel prostate-specific kallikrein
PL196260B1 (pl) * 1997-02-25 2007-12-31 Corixa Corp Polipeptyd, cząsteczka DNA, komórka gospodarza, białko fuzyjne, kompozycje farmaceutyczne i szczepionki do leczenia raka prostaty
HUP0203035A3 (en) * 1998-07-14 2007-12-28 Corixa Corp Compositions and methods for therapy and diagnosis of prostate cancer

Also Published As

Publication number Publication date
EP1194571A1 (fr) 2002-04-10
WO2001004143A2 (fr) 2001-01-18
AU6158700A (en) 2001-01-30
WO2001004143A3 (fr) 2001-10-11
JP2003504080A (ja) 2003-02-04

Similar Documents

Publication Publication Date Title
CA2584482C (fr) Derives antigenes associes aux tumeurs de la famille mage, et sequences d'acides nucleiques codant ces derives, utilises pour la preparaiton de proteines de fusion et de compositions destinees a la vaccination
ES2272012T3 (es) Proteinas de fusion que comprenden proteinas tat y/o nef de vih-1.
AU2001258102B2 (en) Immunogenic polypeptides encoded by mage minigenes and uses thereof
US20080187535A1 (en) Vaccine
CZ20022756A3 (cs) Prostředky a způsoby pro léčení a diagnostiku rakoviny prostaty
CA2401070A1 (fr) Compositions et methodes destinees au diagnostic et a la therapie du mesotheliome malin
US20020150588A1 (en) SPAS-1 cancer antigen
CA2378846A1 (fr) Vaccin
CN109963587A (zh) 丙型肝炎病毒免疫原性组合物及其使用方法
WO2006023598A2 (fr) Peptides restreints par mhc classe ii derives d'antigenes specifiques a la prostate et leur utilisation dans des vaccins destines a traiter ou a prevenir le cancer de la prostate
US6818751B1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
US20060140965A1 (en) Immunogenic compositions comprising a xenogenic prostate protein p501s
US20030143240A1 (en) Prostase protein vaccine comprising derivatised thiol residues and methods for producing said antigen
CA2412089A1 (fr) Vaccin de proteines de prostase contenant des residus thiol derives, et procedes de production dudit antigene
US10316072B2 (en) Immune modulator for immunotherapy and vaccine formulation
WO2002000708A2 (fr) Vaccin
US20080089929A1 (en) Fusion proteins comprising hiv-1 tat and/or nef proteins
JP2008518584A (ja) カニクイザルの前立腺特異的抗原
JP2008502905A (ja) ヒト前立腺疾患に対する作用物質のスクリーニング法

Legal Events

Date Code Title Description
FZDE Discontinued